Prothrombin complex concentrate administration timing in warfarin-associated intracranial hemorrhage

Area of Science:

• Neurology
• Hematology
• Emergency Medicine

Background:

• Current guidelines advocate for rapid reversal of anticoagulation in warfarin-associated intracranial hemorrhage (ICH).
• However, specific time goals for reversal agent administration and their impact on hematoma expansion are not well-defined.
• Limited research exists on the association between time to reversal and outcomes in ICH patients.

Purpose of the Study:

• To evaluate the association between the time to administration of 4-factor prothrombin concentrate (4F-PCC) and the achievement of effective hemostasis in warfarin-associated ICH.
• To determine if 4F-PCC administration timing influences hematoma expansion rates in ICH patients.
• To assess the impact of 4F-PCC administration timing on key clinical outcomes.

Main Methods:

• Retrospective, observational, single-center study.
• Patients with warfarin-associated ICH were stratified into three groups based on time from CT diagnosis to 4F-PCC administration: <45 min, 45-90 min, and >90 min.
• Primary outcome: rates of effective hemostasis, defined as ≤20% hematoma volume increase.

Main Results:

• A total of 39 patients were included in the analysis.
• No significant difference in the primary outcome (effective hemostasis) was observed among the three time-based groups (85.7% vs. 73.3% vs. 90%, p=0.514).
• Secondary outcomes, including in-hospital mortality and length of stay (LOS), also showed no significant differences between groups.

Conclusions:

• Time to administration of 4-factor prothrombin concentrate (4F-PCC) was not associated with the achievement of effective hemostasis in patients with warfarin-associated ICH.
• Hematoma expansion rates were similar across different time intervals for 4F-PCC administration.
• These findings suggest that immediate administration may not be critical for hemostasis in this patient population.